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Summary
Background : The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index is a self-administered validated questionnaire
for patients with osteoarthritis (OA) of the hip or knee. The electronic touch screen version of the WOMAC (e-WOMAC) has been previously
shown to be highly correlated with the original paper format. However, whether the e-WOMAC would be suitable for monitoring the effects of
drug treatment is unknown.
Aim : To validate the longitudinal use of the e-WOMAC questionnaire and its ability to detect changes in WOMAC-scores induced by drug
treatment in outpatient care.
Methods : Fifty-three outpatients, men and women (mean age: 64 years; SDG 9.5), with symptomatic osteoarthritis of hip or knee were
included in an open label study with rofecoxib. At three visits over 3 weeks, responsiveness of the WOMAC 3.1 regarding the three subscales,
pain, stiffness and function, were compared for the original paper format and the computer touch screen format (QUALITOUCH) using
a Likert scale. WOMAC scores were transformed to the 0e100 scale. ANOVA for repeated measures was used for analysis and effect sizes
by subscale were compared for both formats.
Results : Responsiveness for all three subscales was similar between formats. In both formats, pain and stiffness were signiﬁcantly reduced
with rofecoxib as early as 7 days, while functional ability was signiﬁcantly increased (P! 0.01 for all aggregate subscale scores) with
continuing improvement until the end of study. The effect sizes by subscale between Day 1 and 21 were not statistically different between the
paper and the electronic version of the questionnaire and showed similar clinically meaningful improvements in WOMAC scores over 3 weeks.
Conclusion : In this longitudinal intervention study, the e-WOMAC OA Index 3.1 showed similar responsiveness in detecting clinically
meaningful changes than the original paper format.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis Index was developed for standardized as-
sessment of osteoarthritis (OA) symptoms in hip and/or
knee joints1. The WOMAC OA Index covers the domains of
pain, stiffness and function in 5, 2 and 17 questions,
respectively. This index has been extensively validated for
measuring changes after different interventions in patients
with OA2 and is the most widely recommended disease-
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Received 23 November 2003; revision accepted 11 August 2004.91speciﬁc questionnaire for core set assessment in clinical
trials for knee and hip OA established by the Osteoarthritis
Society Task Force, as proposed at the third conference on
outcome measures in rheumatoid arthritis clinical trials
(OMERACT III)3.
In daily clinical practice the WOMAC questionnaire is
a suitable tool for optimizing patient monitoring as the data
are directly provided by the patient and are very re-
producible. However, the paper format does not allow for
an immediate display of results. The e-WOMAC was
designed to improve patient monitoring by its simple design
and provides the opportunity to discuss results with the
patients or the team that takes care of the patients in
a timely fashion, as results are available immediately and
can be shared electronically4. Another advantage of the
e-WOMAC may be its presentation format, where each
question is displayed as text and a situational cartoon,
and are verbalized over the loudspeaker (QUALITOUCH2
913Osteoarthritis and Cartilage Vol. 12, No. 11method). This may be appreciated especially by the older
patients. The electronic formats of the WOMAC-Index 3.0
have been previously validated5e7.
Of special clinical and scientiﬁc interest is the ability of
a questionnaire to detect and monitor improvement or
worsening of the clinical situation based on an intervention.
We therefore compared the responsiveness of the original
paper format and the computer touch screen format to
rofecoxib treatment in patients with symptomatic hip or knee
OA over a course of 3 weeks. The aim of this study was to
validate the longitudinal responsiveness of the e-WOMAC
questionnaire.
Fig. 1. (a) QUALITOUCH multimedia 3-D interactive interfaced
questions answered by touching one of the squares of the Likert
scale on the computer screen. (b) Screen display of the electronic
touch screen featuring question 6 of the WOMAC 3.1 OA Index and
the Likert scale. Translation: SteiﬁgkeitZ stiffness. Wie stark ist
Ihre Gelenksteiﬁgkeit nach dem ersten Aufwachen am Mor-
gen?Z how important is the stiffness of your joints after the ﬁrst
awakening in the morning. KeineZ none. LeichteZmild. Ma¨ssi-
geZmoderate. StarkeZ severe. ExtremeZ extreme. Frage wie-
derholenZ repeat question. Befragung abbrechenZ stop
interview. HilfeZ help. Vorherige FrageZ previous question.
Na¨chste FrageZ next question.Patients and methods
Three sites that participated in the previously published
SVIS-Study, with 136 recruited patients and 22 sites in
total5, participated in this ancillary e-WOMAC protocol and
53 eligible consecutive outpatients were recruited and
included in the evaluation. The SVIS-study was a pro-
spective open label 3 weeks multicenter study to document
the effect of rofecoxib in patients with painful radiograph-
ically proven primary OA of the knee or the hip according to
ACR criteria who were dissatisﬁed with their prior NSAID
treatment (because of either non-responsiveness to or
adverse events from previous NSAID-therapy, including
celecoxib). At inclusion the patients stopped their previous
NSAID therapy and started therapy with rofecoxib 25 mg
once daily on the following day (t0) for 3 weeks, after
which the ﬁnal visit took place (t2), with an interim visit on
day 7 (t1)
5.
Because the core study was a clinical trial with drug
intervention, conducted according to GCP guidelines and
the e-WOMAC is not yet a validated format of the
questionnaire acceptable to regulatory authorities, we had
to renounce to block randomize the patients for the paper vs
the electronic format of the questionnaire. However, all
patients gave their separate written informed consent
before their participation in this ancillary study. At all three
visits, the patients ﬁlled in the paper format of the WOMAC
ﬁrst, followed by the electronic format.
The validated German paper format of the WOMAC 3.1
with a Likert scale was used8,9. The electronic format of the
WOMAC was identical to the German questionnaire with an
identical Likert scale in a computerized touch screen format,
which has been previously shown to have very good
agreement with the original paper format in its numeric
rating scale format6. The QUALITOUCH data capture
method was developed to facilitate patient assessment. The
QUALITOUCH computer program offers a multimedia 3-D
interactive interface: the questions are displayed on
a 34.3 cm diameter screen as a text and a situational
cartoon and are verbalized over the loudspeaker. The
questions are answered by touching one of the squares of
the Likert scale on the computer screen [Fig. 1(a)]. By using
ﬁve buttons on screen the patient could exit the question-
naire, get help, have the question repeated or move only
one question forward or backward [Fig. 1(b)]. It is therefore
possible to leave out one question and move to the next.
Furthermore, the help function self activates after 15 s of
inactivity and presents the next possible steps to the
patient. Patients are not able to see their prior scores.
STATISTICS
Descriptive statistics included the mean of the aggre-
gated scores, the standard deviation and the mean dif-
ference between the scores of the paper and computerized
Table I
Patient demographics
Male (nZ 32) Female (nZ 21) Total (nZ 53)
Age in years
(meanGSD)
63.2G 10.3 65.7G 8.1 64.2G 9.5
Height in cm
(meanGSD)
175.5G 5.3 162.0G 6.8 170.1G 8.9
Weight in kg
(meanGSD)
86G 15.3 75.7G 17.3 81.9G 16.8
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Comparative table of the effect of rofecoxib by format (paper vs electronic) and by WOMAC standardized subscale score over time,
meanG SD
Subscale Format t0 t1 t2 Effect size t2 vs t0
Pain Paper 39.7G 14.5 33.7G 15.7 28.6G 14.8 0.76
e-WOMAC 42.3G 15.2 34.6G 15.6 29.2G 14.6 0.88*
Stiffness Paper 43.4G 18.9 36.5G 15.7 31.1G 20.0 0.63
e-WOMAC 46.1G 22.2 38.6G 18.1 33.4G 20.8 0.59*
Function Paper 44.1G 14.0 38.4G 15.4 32.8G 16.2 0.75
e-WOMAC 43.8G 14.3 38.9G 16.2 32.0G 16.2 0.77*
*Difference between paper vs electronic format scores statistically not signiﬁcant.format. To detect possible format (paper vs computer), time
(t0Z baseline vs t1Z visit 1 at day 7 vs t2Z visit 3 at day
21), scale (pain vs stiffness, vs function) or gender (male vs
female) related effects, a variance analysis by ‘‘repeated
measures ANOVA’’ was performed. In addition, the
standardized mean difference was used to measure the
effect size by WOMAC subscale between t0 and t2 (effect
sizeZ [{mean score t2mean score t0}/{pooled SD}] and
tested for signiﬁcance of the paper vs the electronic format.
All statistical tests were performed at a signiﬁcance level of
0.01 or lower to correct for multiple testing. Normality of the
distribution was tested by KolmogoroveSmirnov. All statis-
tical analyses were performed with SAS StatView 5.01.
Results
PATIENTS
All consecutive 53 patients recruited in the three
participating study centers were included in the analysis
and completed both formats of the questionnaire in all three
visits. The detailed patient characteristics are shown in
Table I. Age and gender were balanced. Forty-three
patients (81%) had primary unilateral knee osteoarthritis,
5 (9%) primary bilateral knee OA, 4 (8%) primary idiopathic
hip OA and 1 (2%) had secondary hip OA after congenital
hip dysplasia. The time needed to answer all questions in
the electronic format of the WOMAC 3.1 was
12.9G 2.7 min vs 12.5G 3.5 min for the paper format (not
signiﬁcant).
WOMAC-SCORES
WOMAC baseline scores by subscale were not signiﬁ-
cantly different by format (electronic or paper) and the effect
size by subscale between t0 and t2 was not signiﬁcantly
different by format (Table II). The overall effect size
between t0 and t2 was 0.71 for the paper version and 0.74
for the electronic version and was statistically not signiﬁ-
cant. Therefore, the responsiveness by subscale was not
signiﬁcantly different between the electronic and the paperversions of the WOMAC. At visit 1 (t1Z day 7) pain and
stiffness were signiﬁcantly reduced with rofecoxib, while
function was signiﬁcantly increased (P! 0.01, Table III).
The mean magnitude of the effect of rofecoxib was
continuously increasing over time in all three subscales
and in both formats. Comparing baseline (t0) to visit 2 (day
21), pain decreased by 30%, stiffness by 28% and function
increased by 26% irrespective of whether the paper or the
electronic format of the WOMAC 3.1 was used (Fig. 2).
While the format (paper vs electronic) might have had some
inﬂuence on the stiffness scale and on the total WOMAC
Index, the format! time interaction of WOMAC 3.1 scores
between the paper and the electronic formats at t0
(baseline), t1 (day 7) and t2 (day 21) were not signiﬁcantly
different for pain (PZ 0.22), stiffness (PZ 0.895), func-
tional ability (PZ 0.542) and for the total WOMAC Index
(PZ 0.508), indicating that the pattern of changes in
WOMAC scores and subscores over time did not differ by
format (Fig. 3). The time! format! scale interaction was
not signiﬁcant, indicating that the pattern of changes of the
WOMAC scores was the same for both formats and all
scales (Table IV). Gender had no inﬂuence on the results.
Discussion
This is the ﬁrst longitudinal study documenting repeated
measures with electronic data capturing through patient
self-assessment. Electronic data capturing has become
increasingly popular for data acquisition in clinical trials.
However, the data collected usually refers to laboratory or
diagnostic examination values or to patient history and data
entry is usually performed by medical or paramedical
personnel. In daily clinical care, there is little experience
with patient self-assessment using standardized question-
naires and almost no related validated tools exist. One
study documents the initial evaluation of an electronic
format of the Short Form 36, concluding that electronic data
collection is acceptable to patients and feasible in a clinical
setting while providing comparable responses to those of
the paper format, improving data capture and being
immediately available10.Table III
Effect of time (t0, t1, t2), format (paper vs electronic) and time! format interaction on the WOMAC subscales and the WOMAC Index
t0, t1* t1, t2* t0, t2* Format** Time! format*
Pain subscale 6.86 (PZ 0.0002) 5.27 (PZ 0.0041) 12.14 (P! 0.0001) 1.33 (PZ 0.0119) PZ 0.22
Stiffness subscale 7.73 (PZ 0.0003) 4.77 (PZ 0.0243) 12.5 (P! 0.0001) 2.73 (PZ 0.0078) PZ 0.895
Function subscale 5.32 (PZ 0.0018) 6.25 (PZ 0.0003) 11.58 (P! 0.0001) 0.26 (PZ 0.5770) PZ 0.542
WOMAC 3.1 Index 6.64 (P! 0.0001) 5.43 (PZ 0.0008) 12.07 (P! 0.0001) 1.27 (PZ 0.0049) PZ 0.508
*Signiﬁcant if P! 0.0033. **Signiﬁcant if P! 0.01.
915Osteoarthritis and Cartilage Vol. 12, No. 11Patient self-assessment by electronic data capturing
presents numerous advantages in clinical care: the data
collection is standardized and the impact of potential
external inﬂuences, which may vary in nature from visit to
visit, is limited; the data may be collected anonymously
across departments, hospitals and medical practices allow-
ing for constant optimization of patient management
techniques by detecting outliers regarding treatment
-25.67%
-28.27%-28.14% -27.00%
-27.59%
-30.97%
-40.00%
-30.00%
-20.00%
-10.00%
0.00%
PAPER
ELECTRONIC
PAIN FUNCTIONSTIFFNESS
* n.s. electronic vs. paper version
*
*
*
Fig. 2. Evolution of WOMAC 3.1 subscales with rofecoxib one tablet
once daily over 3 weeks, paper vs electronic evaluation.success. When performed in the waiting-room, self-assess-
ment makes the best use of the patient’s and the
physician’s time and is a valuable contribution to the
patientephysician interaction, especially in the decision-
making process of treatment adaptations. In contrast with
paper questionnaires which are archived in the patient’s ﬁle,
electronic data allow for easy treatment effect monitoring at
a glance. With the e-WOMAC, the patient’s progress is
documented for the three subscales: pain, stiffness and
function. Multiple assessments over time are displayed on
one page displaying the change over time in an easy to
read graph. The e-WOMAC data collection by patient self-
assessment with a QUALITOUCH touch screen interface
has been shown to have very good agreement in all three
subscales with the original paper format of the question-
naire6. In another study, the patient preference for the
electronic vs the paper format of the questionnaire was
documented: although 54% of the patients had no
experience with computers at all, only 9% preferred the
paper format, 91% either preferring the computer format
(51%) or being indifferent (38%). Ninety-four percent of the
patients declared that the 3-D environment presented (text,
sound and cartoon) was helpful7.
This study shows that e-WOMAC is responsive to
treatment over time with regard to pain, stiffness and
function. In addition, no signiﬁcant difference was found
while comparing the degree of responsiveness by subscale
between the electronic and the paper format of the0
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Fig. 3. Changes in mean WOMAC subscales and in WOMAC Index (G95% conﬁdence intervals), by visit at t0 (baseline), t1 (day 7) and t2
(day 21), paper vs computer format, with rofecoxib one tablet once daily.
916 R. Theiler et al.: Responsiveness of WOMAC 3.1 indexquestionnaire. This suggests that the e-WOMAC is as
responsive as the original paper format. As the main
endpoints of the SVIS study were to document the effects of
rofecoxib on Quality of Life (measured by the SF-12) and
disease speciﬁc symptoms (measured by the WOMAC
paper questionnaire) and because at the time of the
initiation of the SVIS study the e-WOMAC was not
completely validated, we renounced to randomize for the
two formats (paper and electronic) and asked all patients to
ﬁll in the paper format of the questionnaire consistently
before they ﬁlled in the electronic format, accepting thereby
a systematic error in the validation procedure. As a single
parameter, the format seemed to have an inﬂuence on the
WOMAC score, the signiﬁcance being driven by the two
questions related to pain (Table V). In this study, the overall
effect size between t0 and t2 reached 0.71 when measured
with the paper version of the WOMAC and 0.74 with the
electronic version. An effect size between 0.2 and 0.5 is
considered as small but clinically meaningful, while a large
effect size is estimated at being 1.0 or more11. Therefore
the observed effect size of rofecoxib between t0 and t2
should be considered not only statistically signiﬁcant but
also clinically relevant. In contrast the difference in effect
size of 0.03 observed between the paper and the electronic
version of the WOMAC is statistically non-signiﬁcant and
should be considered as clinically irrelevant. This holds true
for all three subscales of the WOMAC, the largest observed
difference in effect size between formats being 0.12.
Furthermore, the paper and the electronic formats of the
WOMAC have proven to be very similar for the monitoring
of treatment effects and under the premises that the choice
for the paper or the electronic format is made upfront and
carried out throughout the timecourse of the observation,
Table IV
WOMAC Index: levels of significance with repeated measures
ANOVA with one, two or three factors
Effect P value Interpretation
Time*
(t0, t1, t2)
!0.0001 Rofecoxib signiﬁcantly
improved WOMAC score
over time
Format* (paper
vs e-WOMAC)
0.0049 Format had an inﬂuence
on WOMAC score
Scale* (pain vs
stiffness vs function)
0.0183 Subscale had no inﬂuence
on WOMAC score
Time! format* 0.5077 Changes of WOMAC scores
over time were the same
for both formats
Time! scale* 0.7229 Changes of WOMAC scores
over time were the same
for all WOMAC subscales
Time! format! scale* 0.7703 Patterns of change in
WOMAC scores over time
did not differ by version
and scale
*Signiﬁcant if P! 0.01.
Table V
Influence of the version in relation with the section of the
questionnaire
Questions addressing Number of questions Signiﬁcance level
Pain 5 0.012
Stiffness 2 0.0078
Function 17 0.577
*Signiﬁcant if P! 0.01.both formats can be considered as equivalent. In the
meantime, another study with correct block randomization
has demonstrated the patient’s preference for the electronic
format and the perfect interchangeability of the paper and
the electronic formats7.
In patients with symptomatic OA at the hip or knee
treated with rofecoxib, the paper and the electronic format
of the WOMAC 3.1 showed similar effect sizes and were
equally suitable for the longitudinal monitoring of the effects
of drug treatment and the detection of clinically meaningful
changes. The future successful use of the e-WOMAC by
the QUALITOUCH method in medical care will depend on
its integration in the daily processes of patient management
at the primary care physician level.
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